Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Relatlimab · Opdualag, BMS-986016

Monoclonal antibody · Antagonist of LAG-3 · developed by E.R. Squibb & Sons, L.L.C.

Approved FDA, Mar 2022

BMY Developer

3 Registered trials

What is Relatlimab?

Relatlimab is a human IgG4 monoclonal antibody that binds to LAG-3 and blocks its interaction with MHC II, reducing LAG-3-mediated immune inhibition. This promotes T cell proliferation and cytokine secretion.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Opdualag, BMS-986016
Drug type: Monoclonal antibody
Targets: LAG-3, MHC II (binding partner it blocks)
Mechanism: Antagonist of LAG-3
Pathways: T cell activation, immune response
Therapy area: Oncology
Developer: E.R. Squibb & Sons, L.L.C. (BMY)
FDA status: Approved as Opdualag (March 18, 2022), BLA761234 · FDA label
UNII: AF75XOF6W3

✅ FDA-approved uses

Unresectable or metastatic melanoma

From the indications section of the FDA label (version of Jun 8, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06561386	Phase 3	Non-small Cell Lung Cancer	Recruiting	BMY
NCT03899155	Phase 2	Cancer	Recruiting	BMY
NCT03026140	Phase 2	Colon Carcinoma	Recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancerColon CarcinomaNon-small Cell Lung Cancer

Other drugs acting on LAG3

Favezelimab Phase 1/2 Fianlimab Phase 1/2 Tobemstomig Phase 1/2

More from E.R. Squibb & Sons, L.L.C.

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Repotrectinib FDA approved Xanomeline FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Relatlimab

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z